News and events

PrecisionLife at Precision Med Tri-Con

Written by PrecisionLife | Jan 21, 2025 2:57:53 PM

PrecisionLife CEO, Steve Gardner, is speaking at the 32nd Annual Precision Med Tri-Con in San Diego from 11-13 March 2025.





Omics, Data, and AI in Precision Medicine

12PM, Wednesday 12 March |  San Diego, CA

  • Steve Gardner, CEO and Co-founder, PrecisionLife
  • Kyle Farh, Vice President & Distinguished Scientist, Artificial Intelligence Lab, Illumina
  • Ryan Taft, Senior Vice President, Genomics R&D, Tempus AI
  • Pankaj Vats, Senior Bioinformatics/Genomics Scientist, NVIDIA
Moderated by Fay Lin, Senior Editor, Genetic Engineering & Biotechnology News.

The promise of AI for understanding disease biology, drug discovery, and diagnostics hinges on the rise of large omics datasets. In this panel, experts from Tempus AI, Illumina, and PrecisionLife will explore the key considerations for omics data generation and curation. They'll also discuss crucial data challenges, such as accessibility and representation, that might prevent AI from reaching its full potential in precision medicine.

 

About PrecisionLife


PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases, which account for over 80% of healthcare spending. Their growing prevalence is making healthcare increasingly unaffordable in all major economies.

The AI-led PrecisionLife platform is unparalleled in its understanding of disease biology – identifying the underlying causes of disease and biomarkers to stratify patients by molecular mechanism for the first time in complex conditions. This enables us to accurately link individuals to the drug targets, clinical trials and treatments that will benefit them – leading to earlier, more accurate and effective disease prediction, diagnosis, treatment, and prevention.

Our unique disease insights and precision medicine tests hold the key to increasing the rate of success in drug development, reducing the global burden of chronic diseases, and improving health for billions of people.